Evidence map›Paper›PMID 35579816›Full record

ArticleDrug safety2022

Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.

Guillaume L Martin, Julien Jouganous, Romain Savidan, Axel Bellec, Clément Goehrs, Mehdi Benkebil, Ghada Miremont, Joëlle Micallef, Francesco Salvo, Antoine Pariente and 2 more

Abstract read
In one paragraph

Article in Drug safety, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Observational
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Guillaume L MartinSynapse Medicine, 3 rue Lafayette, 33000, Bordeaux, France.
Julien JouganousSynapse Medicine, 3 rue Lafayette, 33000, Bordeaux, France.
Romain SavidanSynapse Medicine, 3 rue Lafayette, 33000, Bordeaux, France.
Axel BellecSynapse Medicine, 3 rue Lafayette, 33000, Bordeaux, France.
Clément GoehrsSynapse Medicine, 3 rue Lafayette, 33000, Bordeaux, France.
Mehdi BenkebilSurveillance Division, Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), Saint Denis, France.
Ghada MiremontUniversity of Bordeaux, INSERM, BPH, U1219, Team Pharmacoepidemiology, Bordeaux, France.
Joëlle MicallefCRPV Marseille Provence Corse, Service Hospitalo-Universitaire de Pharmacologie Clinique et Pharmacovigilance, Assistance Publique Hôpitaux de Marseille, Marseille, France.
Francesco SalvoUniversity of Bordeaux, INSERM, BPH, U1219, Team Pharmacoepidemiology, Bordeaux, France.
Antoine ParienteUniversity of Bordeaux, INSERM, BPH, U1219, Team Pharmacoepidemiology, Bordeaux, France.
Louis LétinierSynapse Medicine, 3 rue Lafayette, 33000, Bordeaux, France. louis@synapse-medicine.com.ORCID http://orcid.org/0000-0001-5082-4866
French Network of Pharmacovigilance Centres

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAdverse drug reaction reports are usually manually assessed by pharmacovigilance experts to detect safety signals associated with drugs. With the recent extension of reporting to patients and the emergence of mass media-related sanitary crises, adverse drug reaction reports currently frequently overwhelm pharmacovigilance networks. Artificial intelligence could help support the work of pharmacovigilance experts during such crises, by automatically coding reports, allowing them to prioritise or accelerate their manual assessment. After a previous study showing first results, we developed and compared state-of-the-art machine learning models using a larger nationwide dataset, aiming to automatically pre-code patients' adverse drug reaction reports.

objectivesWe aimed to determine the best artificial intelligence model identifying adverse drug reactions and assessing seriousness in patients reports from the French national pharmacovigilance web portal.

methodsReports coded by 27 Pharmacovigilance Centres between March 2017 and December 2020 were selected (n = 11,633). For each report, the Portable Document Format form containing free-text information filled by the patient, and the corresponding encodings of adverse event symptoms (in Medical Dictionary for Regulatory Activities Preferred Terms) and seriousness were obtained. This encoding by experts was used as the reference to train and evaluate models, which contained input data processing and machine-learning natural language processing to learn and predict encodings. We developed and compared different approaches for data processing and classifiers. Performance was evaluated using receiver operating characteristic area under the curve (AUC), F-measure, sensitivity, specificity and positive predictive value. We used data from 26 Pharmacovigilance Centres for training and internal validation. External validation was performed using data from the remaining Pharmacovigilance Centres during the same period.

resultsInternal validation: for adverse drug reaction identification, Term Frequency-Inverse Document Frequency (TF-IDF) + Light Gradient Boosted Machine (LGBM) achieved an AUC of 0.97 and an F-measure of 0.80. The Cross-lingual Language Model (XLM) [transformer] obtained an AUC of 0.97 and an F-measure of 0.78. For seriousness assessment, FastText + LGBM achieved an AUC of 0.85 and an F-measure of 0.63. CamemBERT (transformer) + Light Gradient Boosted Machine obtained an AUC of 0.84 and an F-measure of 0.63. External validation for both adverse drug reaction identification and seriousness assessment tasks yielded consistent and robust results.

conclusionsOur artificial intelligence models showed promising performance to automatically code patient adverse drug reaction reports, with very similar results across approaches. Our system has been deployed by national health authorities in France since January 2021 to facilitate pharmacovigilance of COVID-19 vaccines. Further studies will be needed to validate the performance of the tool in real-life settings.

Indexed as

COVID-19Drug-Related Side Effects and Adverse ReactionsAdverse Drug Reaction Reporting SystemsArtificial IntelligenceCOVID-19 VaccinesHumansPharmacovigilanceCOVID-19 Vaccines

Identifiers

PMID35579816
PMCPMC9112264

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.